News
Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...
Amgen (NASDAQ:AMGN) and Zai Lab (NASDAQ:ZLAB) said on Monday that a late-stage trial testing the combination of bemarituzumab ...
Hosted on MSN9h
2 Dividend Stocks to Buy on the Dip and Hold ForeverAmgen is seeking its next blockbuster medicine ... The medicine led to an average weight loss of about 20% after 52 weeks, with no plateau observed. And importantly, MariTide is administered once a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback